Clinical Trials
28
11 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1911
Active, not recruiting
1
3.6%
Completed
7
25.0%
Not yet recruiting
10
35.7%
Recruiting
7
25.0%
Unknown
3
10.7%
No approval data available
- At least 105 elite American scientists have defected to Chinese institutions since 2024, with nearly half specializing in biotechnology and medicine. - High-profile recruits include Harvard chemist Charles Lieber, Nobel laureate Omar Yaghi, and leading virologist Haitao Hu, drawn by multimillion-dollar funding and advanced laboratories. - China's government R&D spending surged 90% to $133 billion from 2013 to 2023, while the country surpassed the US in clinical trial volume in 2024. - Experts warn the talent exodus threatens US national security and competitive advantage in drug development, as scientists cite fewer regulatory restrictions in China.
- China's NMPA approved the world's first product standard for AI-powered brain-computer interface medical devices processing EEG data, effective September 1, 2027. - The standard sets uniform technical requirements and testing methods across five EEG data stages: collection, processing, labeling, storage, and access. - No FDA, EMA, or ISO equivalent addresses EEG training-data quality, though FDA issued draft AI device guidance in January 2025 and ISO/IEC TS 27571:2026 covers data format. - The standard is the latest piece of China's BCI regulatory architecture, which includes the commercially approved Neuracle NEO implant and rapid reimbursement integration.
- Tsinghua University researchers developed TNFR1TIF cells, engineered CAR-T cells that capture and degrade soluble TNF through receptor-mediated endocytosis, functioning as a self-renewing living drug. - A single infusion prevented and treated all stages of RA in human TNF-transgenic mice, matching the efficacy of repeated high-dose adalimumab without redosing or anti-drug antibody risk. - CRISPR-Cas9 co-deletion of Bcor and Zc3h12a enabled robust expansion and over one-year persistence in fully immunocompetent mice without lymphodepleting preconditioning. - The platform represents a conceptual shift, extending CAR-T therapy from cell-surface antigens to soluble extracellular proteins, with potential applications in other cytokine-driven diseases and Alzheimer's.
- Professor Huji Xu received the Flinders University Convocation Medal for pioneering the world-first allogeneic CAR-T cell therapy for autoimmune diseases, which may enable damaged immune systems to be "reset." - His landmark study was the first to use engineered immune cells to target cells mistakenly attacking the body's own tissues, potentially leading to remission in autoimmune disease. - Professor Xu is now focused on developing cost-effective cell therapies that are safer, faster to deliver, and more affordable, citing industrial mass-production as a key advantage of allogeneic CAR-T. - The award was presented among 10 exceptional alumni at a ceremony in Adelaide Town Hall on 28 August, recognising his research into the genetic drivers of autoimmune disease.
- Chinese researchers at Tsinghua University have developed DrugCLIP, an AI-powered virtual drug screening platform that achieves a million-fold increase in screening speeds compared to conventional molecular docking methods. - The platform enabled the first-ever virtual screening project on a human-genome scale, analyzing over 500 million drug-like molecules across 10,000 protein targets and yielding more than 2 million potential active compounds. - DrugCLIP compresses what would take centuries of computation into a single day on one computing node, creating the largest known protein-ligand screening database that is freely available to the global scientific community. - The breakthrough technology reformulates traditional molecular docking as high-efficiency semantic search, with the platform already serving over 1,400 users and completing more than 13,500 screening tasks within six months.
- MindRank's MDR-001 becomes China's first AI-assisted Category 1 new drug to reach Phase 3 clinical trials, targeting weight loss through GLP-1 receptor agonism. - The AI-driven development process reduced traditional timelines from 7-10 years to 4.5 years while cutting R&D costs by at least 60 percent. - Beijing's Global Health Drug Discovery Institute launched AI Kongming platform to accelerate drug development for global health challenges including tuberculosis and malaria. - Both developments represent China's growing leadership in AI-powered pharmaceutical innovation and computational drug design capabilities.
- Stanford researchers have developed CRISPR-GPT, an AI-powered system that serves as a "copilot" for gene editing experiments, providing step-by-step guidance and reducing the time needed to develop new treatments from years to months. - The multi-agent system outperformed general AI models like GPT-3.5 and GPT-4 in accuracy and reliability across nearly 300 experimental scenarios, with junior researchers achieving 80-90% editing efficiency in real laboratory tests. - CRISPR-GPT democratizes gene editing by lowering barriers to entry for novice researchers while incorporating safety guardrails to prevent unethical applications, potentially accelerating the development of life-saving therapies.
- Bayer and Tsinghua University have extended their strategic research collaboration by three additional years, building on a 16-year partnership that has produced over 70 joint research projects and more than 10 publications in top international journals. - The extended agreement focuses on joint research targeting oncology, cardiovascular and renal diseases, neurology, rare diseases, and immunology, reinforcing Bayer's commitment to healthcare innovation in China's rapidly evolving pharmaceutical market. - The partnership has established a benchmark for collaboration between multinational pharmaceutical companies and Chinese academic institutions, with Bayer conducting more than 80% of its major multi-center clinical trials in China. - Bayer's broader China strategy includes two global R&D centers, four production facilities, and the recent launch of Bayer Co.Lab China, which aims to incubate 10-15 biotech startups focusing on cutting-edge therapeutic innovations.
- China's NEO brain-computer interface (BCI) device is set to begin large-scale clinical trials next year, enrolling 30-50 spinal cord injury patients across 10 centers. - The NEO device, developed by Neuracle Technology and Tsinghua University, has already undergone three successful human implantations this year. - A recent surgery enabled a paralyzed patient to regain the ability to move their arms and perform simple tasks via mind control. - Clinical data from these trials will be submitted to regulatory authorities to seek approval for commercialization of the BCI product.
